NCT06029998 2025-11-28
BORXPTEN
University of Utah
Phase 2 Recruiting
Clinical Trials
11 trialsNCT00276614 2020-09-01
Bortezomib in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00103376 2018-11-05
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00183937 2018-05-14
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Completed
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00066352 2015-07-23
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
University Health Network, Toronto
Phase 2 Completed
NCT00425503 2014-04-21
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Baylor College of Medicine
Phase 2 Completed
NCT00025376 2013-09-05
PS-341 in Treating Patients With Metastatic Kidney Cancer
University of Chicago
Phase 2 Completed
NCT00072150 2013-06-05
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00193232 2010-07-28
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00017329 2009-12-15
PS-341 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed